3,9-Dihydroxy-2-prenylcoumestan,
psoralidin,
Psoralidin,
18642-23-4,
3,9-Dihydroxy-2-prenylcoumestan,
UNII-G16ZUQ069L,
G16ZUQ069L,
3,9-Dihydroxy-2-(3-methyl-2-butenyl)-6H-benzofuro(3,2-c)(1)benzopyran-6-one,
Q-100223,
3,9-dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one,
Psoralidin (5),
AC1NQZ4K,
CHEBI:8616,
SCHEMBL3239072,
CHEMBL4064323,
CTK0H8365,
KS-00001FHL,
DTXSID20171903,
BDBM246524,
ZINC899902,
HY-N0232,
LMPK12090007,
MFCD10566617,
AKOS026674261,
CS-3757,
4CN-1277,
AS-18741,
FT-0688287,
P2605,
X1215,
C10523,
3,9-dihydroxy-2-(3-methylbut-2-en-1-yl)-6H-[1]benzofuro[3,2-c][1]benzopyran-6-one,
3,9-Dihydroxy-2-(3-methylbut-2-en-1-yl)-6H-benzofuro[3,2-c]chromen-6-one,
6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-butenyl)-,
C20H16O5,
ACN-047102,
C20-H16-O5,
CID5281806,
6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-butenyl)-,